Strategic partnerships Purna has a global presence and a strong track record as a preferred partner for top-10 pharma multinationals, making it a credible collaborator for expanded CDMO collaborations and co-development opportunities with large players.

Acquisition momentum Recent acquisition by Ampersand Capital Partners and leadership expansions signal strong growth funding and strategic investment, creating opportunities to pursue scaled manufacturing programs and regional expansion with well-capitalized support.

Expansion potential Plans for trans-Atlantic partnerships and cross-border capabilities (notably with MedPharm) indicate a readiness to take on global development and manufacturing projects, including late-stage and marketed product support.

Diversified services Specializing in semi-solid, powders, and liquids with GXP compliance and flexible services positions Purna to win CDMO wins across early to late-stage development, including niche or complex dosage forms.

R&D collaboration Purna’s active search for innovative drugs and its R&D and innovation network create opportunities to source or co-develop new therapeutic candidates and connect them with suitable commercial partners for out-licensing.